Uhl K - Search Results

1

Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development.

Min SS, Turner JR, Nada A, DiMino TL, Hynie I, Kleiman R, Kowey P, Krucoff MW, Mason JW, Phipps A, Newton-Cheh C, Pordy R, Strnadova C, Targum S, Uhl K, Finkle J. Min SS, et al. Among authors: uhl k. Am Heart J. 2010 May;159(5):716-29. doi: 10.1016/j.ahj.2010.02.004. Am Heart J. 2010. PMID: 20435178 Review.

2

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N. Rock EP, et al. Among authors: uhl k. Am Heart J. 2009 May;157(5):827-36, 836.e1. doi: 10.1016/j.ahj.2009.02.020. Am Heart J. 2009. PMID: 19376308 Review.

3

New precompetitive paradigms: focus on cardiac safety.

Finkle J, Bloomfield D, Uhl K, Sanhai W, Stockbridge N, Krucoff MW. Finkle J, et al. Among authors: uhl k. Am Heart J. 2009 May;157(5):825-6. doi: 10.1016/j.ahj.2009.02.021. Am Heart J. 2009. PMID: 19376307 No abstract available.

4

Increasing participation of women in early phase clinical trials approved by the FDA.

Pinnow E, Sharma P, Parekh A, Gevorkian N, Uhl K. Pinnow E, et al. Among authors: uhl k. Womens Health Issues. 2009 Mar-Apr;19(2):89-93. doi: 10.1016/j.whi.2008.09.009. Womens Health Issues. 2009. PMID: 19272558

5

Drug eluting stents and the critical path initiative: Evolving paradigms for safety evaluation.

Sanhai WR, Stockbridge N, Fiorentino RP, Uchida T, Uhl K, Krucoff MW. Sanhai WR, et al. Among authors: uhl k. Drug Discov Today Technol. 2007 Winter;4(2):43-6. doi: 10.1016/j.ddtec.2007.10.004. Drug Discov Today Technol. 2007. PMID: 24980839

6

Advancing women's health via FDA Critical Path Initiative.

Parekh A, Sanhai W, Marts S, Uhl K. Parekh A, et al. Among authors: uhl k. Drug Discov Today Technol. 2007 Winter;4(2):69-73. doi: 10.1016/j.ddtec.2007.10.014. Drug Discov Today Technol. 2007. PMID: 24980844

7

An innovative approach to determine fetal risk: the FDA Office of Women's Health pregnancy exposure registry web listing.

Sharma P, Parekh A, Uhl K. Sharma P, et al. Among authors: uhl k. Womens Health Issues. 2008 Jul-Aug;18(4):226-8. doi: 10.1016/j.whi.2008.02.006. Epub 2008 May 12. Womens Health Issues. 2008. PMID: 18468921 No abstract available.

8

Females in clinical studies: where are we going?

Uhl K, Parekh A, Kweder S. Uhl K, et al. Clin Pharmacol Ther. 2007 Apr;81(4):600-2. doi: 10.1038/sj.clpt.6100112. Epub 2007 Feb 21. Clin Pharmacol Ther. 2007. PMID: 17314925

9

Improving women's health through modernization of our bioinformatics infrastructure.

Oliva A, Pinnow E, Levin R, Uhl K. Oliva A, et al. Among authors: uhl k. Clin Pharmacol Ther. 2008 Jan;83(1):192-5. doi: 10.1038/sj.clpt.6100437. Epub 2007 Nov 7. Clin Pharmacol Ther. 2008. PMID: 17987048

10

The Food and Drug Administration Office of Women's Health: impact of science on regulatory policy.

Obias-Manno D, Scott PE, Kaczmarczyk J, Miller M, Pinnow E, Lee-Bishop L, Jones-London M, Chapman K, Kallgren D, Uhl K. Obias-Manno D, et al. Among authors: uhl k. J Womens Health (Larchmt). 2007 Jul-Aug;16(6):807-17. doi: 10.1089/jwh.2006.0135. J Womens Health (Larchmt). 2007. PMID: 17678451

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

106 results

Search Page